Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), through its direct ...

Aug 31 (Reuters) - Samsung Biologics will launch its takeover offer for Swiss contract drugmaker PolyPeptide Group in September, the South Korean company said in an offer prospectus on Monday. The ...

South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.

Moscow, Russia--(Newsfile Corp. - August 16, 2023) - Polypeptide.ltd, a frontrunner in delivering exceptional peptide services, proudly announces a substantial expansion of its production capacity.

Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.

South Korea's Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 ​billion) all-cash bid for Swiss contract drugmaker PolyPeptide , ‌the companies said in separate statements.

A research study describes a systematic high-throughput design approach for virtual screening and creation of novel polypeptide-based molecules that form regular secondary structures that can be used ...

The collaboration between Donaldson and PolyPeptide marks a milestone in the pharmaceutical industry's pursuit of environmentally friendly manufacturing practices. By leveraging Donaldson's experience ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.